

**Press release October 25, 2007**

## **Orexo signs distribution agreement with Hospira in Asia for pain product Rapinyl™**

*Orexo AB and the specialty pharmaceuticals and medication delivery company Hospira have signed a distribution agreement that grants Hospira exclusive rights to market and sell Rapinyl™, Orexo's patented product for treatment of break-through pain in cancer, in Asia Pacific markets including Australia and New Zealand. Market rights for the US, the EU and Japan were previously out-licensed, while another distribution agreement has also been signed for the CIS, Bulgaria and Romania.*

“Hospira has a strong market position in cancer treatment, and the company has a well-established distribution network in the Asia Pacific region. Demand for new, effective pain treatments is growing rapidly in this region, and we believe that Hospira will be effectively commercializing Rapinyl™ in all the markets in the territory,” says Zsolt Lavotha, president and CEO of Orexo AB. “For Orexo, distributor agreements are important source for generating additional profitability from Rapinyl on a global basis” he said.

Rapinyl™ is intended for treatment of breakthrough pain in cancer. It is based on Orexo's unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. The new drug form is designed to provide quickly administered, predictable and reproducible pain relief and also results in simplified treatment for patients suffering from breakthrough pain.

“Rapinyl™ is the latest addition to our branded specialty pharmaceutical portfolio in the region and will support our vision of Advancing Wellness for cancer patients across Asia. It compliments our existing oncology and oncology-support product range and our sales and marketing strengths. The Asia Pacific market is growing rapidly, both in terms of patients and access, and this new partnership with Orexo will help our companies improve the life of patients and the effectiveness of their caregivers in the region” added Tim Oldham, President, Asia-Pacific, for Hospira.

The contract with Hospira covers distribution rights in Asia Pacific markets including Australia and New Zealand. Hospira will also be responsible for regulatory approval in these markets. The market rights for Rapinyl™ have been licensed to Kyowa Hakko Kogyo Co. Ltd. for the Japanese market since 2003, to Endo Pharmaceuticals for the North American market since 2004 and to ProStrakan Group plc for the EU since 2005. During 2006, a distribution agreement was signed with Gedeon Richter Ltd. for the CIS (Russia and other countries in the former Soviet Union), Bulgaria and Romania.

### **For further information, please contact:**

Zsolt Lavotha, President & CEO, Orexo

Tel: +46 (0)18 - 780 88 12

Email: [zsolt.lavotha@orexo.com](mailto:zsolt.lavotha@orexo.com)

Claes Wenthzel, Executive Vice President & CFO, Orexo  
Tel: +46 (0)18- 780 88 44  
Email: [claes.wenthzel@orexo.com](mailto:claes.wenthzel@orexo.com)

Tim Oldham, President, Hospira Asia-Pacific  
Tel: +61 3 9868 0347  
Email: [tim.oldham@hospira.com](mailto:tim.oldham@hospira.com)

## NOTES TO EDITORS:

### About Orexo

Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them. By combining approved active substances with Orexo's drug delivery technologies it is possible to significantly enhance their therapeutic value, such as providing quicker onset of action or ease of administration. This business model is aimed at bringing products to market faster with lower development risk and costs.

Orexo, which has its global headquarters and development laboratories in Sweden, currently operates across the world through development, licensing and distribution agreements in all major markets.

Orexo has a balanced portfolio with two products on the market, three in registration and/or late stage clinical phase, one in clinical phase I, one in formulation phase and two in early development phase.

Orexo is listed on the OMX Nordic List Mid Cap (ticker:ORX).  
[www.orexo.com](http://www.orexo.com)

### About Rapinyl™

Rapinyl™ is a patented product for the management of breakthrough cancer pain.

Rapinyl™ also has registration, development and marketing agreements in the following countries:

- US - Endo Pharmaceuticals
- Europe - ProStrakan
- Japan - Kyowa Hakko
- Russia, Romania, Bulgaria - Gedeon Richter

### About Orexo's technology

Orexo's product and development endeavours are based on its innovative expertise in a wide variety of drug delivery formulations, with focus on dry formulations.

### About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™ by developing, manufacturing and marketing products that help improve the productivity, safety and efficacy of patient care. In February 2007, Hospira acquired Mayne Pharma Limited to become the world leader in specialty generic injectable pharmaceuticals. With 70 years of service to the hospital industry, Hospira's portfolio includes one of the industry's broadest lines of generic acute-care and oncology injectables, which help address the high cost of proprietary pharmaceuticals; and integrated solutions for medication management and infusion therapy. Headquartered north of Chicago in Lake Forest, Ill., Hospira has approximately 15,000 employees worldwide. Hospira's news releases and other information can be found at [www.hospira.com](http://www.hospira.com).